Pembrolizumab Induces Responses in Melanoma Patients With Brain Mets

Source: Cancer Network, November 2015

Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases. The data were presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.

About half of metastatic melanoma patients develop brain metastases. “Historically, the brain was considered an ominous site, and survival in older studies is about 2 to 4 months. Whole brain radiation therapy does not clearly impact survival, and controls brain lesions for weeks only,” said Harriet Kluger, MD, professor of medicine (medical oncology) at Yale Cancer Center.
– See more at: http://www.cancernetwork.com/smr-2015/pembrolizumab-induces-responses-melanoma-patients-brain-mets#sthash.WzzoYase.dpuf